Trial Profile
A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Valproic acid (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 13 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2025.
- 13 Mar 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2025.
- 29 Sep 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.